The myomectomy market analysis explains factors such as the increasing incidence of uterine fibroids and the growing demand for minimally invasive surgeries, which drive market growth. Furthermore, the adoption of robotic-assisted surgical technology in myomectomy is expected to introduce new market trends. However, the high cost of new medical devices and myomectomy procedures is expected to hamper the market growth.
Myomectomy is a surgical procedure that encompasses the removal of non-cancerous growth of tissue, known as uterine fibroids or uterine leiomyomas, that develop in the uterus. Myomectomy allows doctors to remove fibroids that cause symptoms while leaving the uterus intact. This means that a woman can continue to have menstrual periods and may choose to become pregnant.
The global burden of UFs has increased in recent years, with a significant increase in incidence and disability-adjusted life years (DALYs) worldwide. According to an article published by Frontiers in November 2022, the estimated occurrence of UFs is between 20% and 77%, and the estimated prevalence is between 40% and 60% among women under the age of 35 and between 70% and 80% among women over the age of 50. In the same article, a study was conducted using statistics from the Global Burden of Disease Study (2021) to observe changes in UF prevalence over 30 years. The study concluded that 3,873,678 new cases of UFs were reported in 2021, representing a growth rate of 67.14% compared to the global incident cases from 1990 to 2021. In this duration, deaths and disability-adjusted life years of UFs worldwide increased by 0.17 and 60.18%, respectively.
Similarly, in an article published by PubMed in 2021, fibroids affect women mainly during their reproductive years, and ~70% of white women and more than 80% of women of African ancestry are diagnosed with fibroids during their lifetime.
This rising prevalence of UFs in women has increased the demand for myomectomy surgery to remove fibroids. For instance, according to a study, “Perioperative Myomectomy Outcomes Based on the Current Coding Rules,” published by the American College of Obstetricians & Gynecologists in July 2022, 8,363 myomectomy procedures were performed from 2014 to 2021, out of which 3,117 (37.3%) were conducted via minimally invasive surgery (MIS) while 5,246 (62.7%) were done through laparotomy. Of the MIS procedures, 2,080 (66.7%) were classified as smaller myomectomies and 1,037 (33.3%) as larger ones.
Advanced surgical instruments, imaging technologies, and robots have made myomectomy procedures precise and less invasive. According to an article published in the Journal of Obstetrics and Gynecology Research in October 2021, a study including sixty-one women with symptomatic fibroids received robotic single-port myomectomy (RSPM) was performed to evaluate the procedure's feasibility. The study concluded that RSPM is a feasible surgical option for women with symptomatic fibroids. It is expected to increase indications of single-port myomectomy by solving ergonomic problems that come with single-port laparoscopic myomectomy.
These technological innovations offer patients shorter recovery times, less scarring, and reduced post-operative complications, leading to a rise in demand. Many companies and healthcare institutions provide advanced surgical procedures to fulfill the demand and gain market value. For instance, in August 2023, Apollo Adlux Hospitals in Kochi launched the 4th generation robotic-assisted surgery system, Da Vinci Xi. This installation is expected to improve clinical outcomes across multiple surgeries at the Departments of Gynecology, Surgical Gastroenterology, and Urology. As a result, more than 90% of patients can go home on the same day as their surgery, leading to a quick recovery period.
Similarly, in April 2023, St. Luke's Medical Center, a leading healthcare institution in the Philippines, announced using the Da Vinci Surgical System for gynecological procedures. With the adoption of robot-assisted surgical technologies, St. Luke's offers Robotic-assisted Laparoscopic Prostatectomy, Robotic-assisted Myomectomy, and Robotic-assisted Hysterectomy. Such a combination of technological advancements gives doctors more control and accuracy during surgery, making it a safe option for patients. Therefore, technological advancements are a standalone factor driving market growth during 2021-2031.
The myomectomy market is segmented based ontype,product
The myomectomy market, by the end user, is segmented into hospitals, specialty clinics, and ambulatory surgical centers. Based on geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Based on type, the myomectomy market is segmented into abdominal, laparoscopic, and hysteroscopic myomectomy. The abdominal myomectomy segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2031. The abdominal myomectomy segment held a significant share in the myomectomy market in 2022 owing to the rising number of patients with UFs undergoing abdominal myomectomy procedures for treatment. Abdominal myomectomy is the most commonly performed and widely preferred treatment for fibroids.
The laparoscopic myomectomy segment is expected to register the highest CAGR from 2022 to 2031. It provides a less invasive approach to myomectomy procedures, resulting in faster patient recovery than other methods. The surgeon removes the fibroids using small instruments inserted through a few small incisions. These benefits of laparoscopic myomectomy are expected to boost growth in this segment during the forecast period.
The myomectomy market, by product, is segmented into laparoscopic power morcellators, harmonic scalpels, hysteroscopes, and others. The other segment held the largest market share in 2022, and the same segment is anticipated to grow fastest from 2022 to 2031. This is attributed to the benefits offered by these instruments, including their ability to facilitate less invasive surgeries, resulting in minimal bleeding without harming the reproductive organs.
Based on end users, the myomectomy market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022. This can be attributed to the rising number of skilled physicians. Hospitals also have better facilities than other surgical centers to perform minimally invasive procedures.
Based on geography, the global myomectomy market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. In 2022, the myomectomy market in North America held the largest global market share. The market in North America is segmented into the US, Canada, and Mexico. The US dominated the market in North America. This can be attributed to various factors, including the increasing number of patients experiencing uterine fibroid problems, the availability of high medical reimbursement facilities in the region, rising government initiatives, and an increase in myomectomies related to surgical procedures and hospital visits. According to the article published by the US Office on Women's Health in February 2021, Fibroids cause symptoms including pain, heavy bleeding, frequent urination, and rectal pressure and are common in women aged 40 to early 50s. ~20% to 80% of women are diagnosed with UFs by age 50.
Additionally, the presence of major companies such as CooperSurgical, Inc.; Medtronic; Stryker Corporation, and Intuitive Surgical, and the availability of technological innovations contribute to the region's market growth. Furthermore, the increasing government healthcare spending creates opportunities for further myomectomy market growth.
The Asia-Pacific region is anticipated to experience high growth during 2021 - 2031. This can be attributed to the increasing number of women suffering from uterine fibroids, greater awareness regarding disease diagnosis and treatment, and the rapid modernization of healthcare infrastructure.
Medtronic; Stryker Corporation; CONMED Corporation; CooperSurgical Inc.; Ethicon, Inc.; Hologic, Inc.; Minerva Surgical, Inc.; INSIGHTEC; Karl Storz GmbH; Intuitive Surgical; and B. Braun Melsungen AG are some of the key companies operating in the myomectomy market. These leading players focus on expanding and diversifying their market presence and clientele, tapping business opportunities in the myomectomy market.
Report ScopeThe regional trends and factors influencing the Myomectomy Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Myomectomy Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 794.81 Million |
| Market Size by 2031 | US$ 1,360.39 Million |
| Global CAGR (2025 - 2031) | 7.98% |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Myomectomy Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Myomectomy Market are:
Disclaimer: The companies listed above are not ranked in any particular order.